Converd Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 41

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 8

Converd General Information

Description

Operator of a research and development platform for novel oncolytic virus therapies intended for the immune system's ability to target and destroy cancer cells. The company offers a comprehensive pipeline built on multiple virus-engineering platforms, enabling integration with immune cell therapies and checkpoint inhibitors, allowing oncologists and researchers to explore combination regimens that aim to convert non-responsive tumors into immunologically active ones and advance potential treatments for a range of cancer patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 7th Floor, Building D-1, Number 2959 Yuhangtang Road, Future Science and Technology City
  • Yuhang District
  • Hangzhou, Zhejiang 311121
  • China
+86 0571
Primary Industry
Enterprise Systems (Healthcare)
Other Industries
Pharmaceuticals
Biotechnology
Corporate Office
  • 7th Floor, Building D-1, Number 2959 Yuhangtang Road, Future Science and Technology City
  • Yuhang District
  • Hangzhou, Zhejiang 311121
  • China
+86 0571

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Converd Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Secondary Transaction - Private 22-Dec-2025 Completed Generating Revenue
10. Later Stage VC 23-Sep-2024 Completed Generating Revenue
9. Secondary Transaction - Private 20-Dec-2022 Completed Generating Revenue
8. Later Stage VC (Series C) 02-Aug-2022 Completed Generating Revenue
7. Secondary Transaction - Private 24-Jun-2022 Completed Generating Revenue
6. Later Stage VC 29-Oct-2021 Completed Generating Revenue
5. Secondary Transaction - Private 01-Feb-2021 Completed Generating Revenue
4. Later Stage VC (Series B) 15-Dec-2017 Completed Generating Revenue
3. Later Stage VC 28-Sep-2017 Completed Generating Revenue
2. Later Stage VC 18-Jul-2017 Completed Generating Revenue
To view Converd’s complete valuation and funding history, request access »

Converd Patents

Converd Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026158643-A1 Therapeutic agent comprising recombinant oncolytic vaccinia virus and antibody-drug conjugate and use thereof Pending 27-Jan-2025
WO-2022057725-A1 Isolated oncolytic adenovirus capable of expressing exogenous gene, vector, therapeutic agent, and use Inactive 16-Sep-2020
EP-4162941-A1 Isolated recombinant oncolytic poxvirus capable of being regulated and controlled by microrna and use thereof Pending 30-Apr-2020
EP-4162941-A4 Isolated recombinant oncolytic poxvirus capable of being regulated and controlled by microrna and use thereof Pending 30-Apr-2020
US-20230265396-A1 Isolated recombinant oncolytic poxvirus capable of being regulated and controlled by microrna and use thereof Pending 30-Apr-2020 C12N7/00
To view Converd’s complete patent history, request access »

Converd Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Converd Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Hangzhou Huafang Chuanghuang Investment Management Corporate Venture Capital Minority
Holley Group Corporation Minority
Lanson Investment Growth/Expansion Minority
Betta Pharmaceuticals Corporation Minority
CR Life Sciences Corporation Minority
You’re viewing 5 of 8 investors. Get the full list »

Converd FAQs

  • When was Converd founded?

    Converd was founded in 2011.

  • Where is Converd headquartered?

    Converd is headquartered in Hangzhou, China.

  • What is the size of Converd?

    Converd has 41 total employees.

  • What industry is Converd in?

    Converd’s primary industry is Enterprise Systems (Healthcare).

  • Is Converd a private or public company?

    Converd is a Private company.

  • What is Converd’s current revenue?

    The current revenue for Converd is .

  • Who are Converd’s investors?

    Hangzhou Huafang Chuanghuang Investment Management, Holley Group, Lanson Investment, Betta Pharmaceuticals, and CR Life Sciences are 5 of 8 investors who have invested in Converd.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process